Találati lista | Tudóstér

001-es BibID:	BIBFORM061229
Első szerző:	Miltényi Zsófia (belgyógyász, haematológus)
Cím:	Prognostic value of interim and restaging PET/CT in Hodgkin lymphoma : results of the CHEAP (Chemotherapy Effectiveness Assessment by PET/CT) study - long term observation. / Z. Miltenyi, S. Barna, I. Garai, Z. Simon, A. Jona, F. Magyari, L. Gergely, Z. Nagy, K. Keresztes, P. Pettendi, A. Illes
Dátum:	2015
Megjegyzések:	Very few studies have determined the prognostic value of interim and restaging PET/CT in patients with Hodgkin lymphoma using current standard of care therapy outside clinical trials. We analyzed the effect of the results of interim and restaging PET/CT on the survival (overall- and relapse-free) in patients who received standard first-line treatment based on the stage of disease and risk factors. We investigated the differences between the relapse and non-relapse groups based on the clinical pathological characteristics of patients who had positive interim PET/CT results. Between January 1, 2007 and December 31, 2011, the staging, interim and restaging PET/CT scans of patients with Hodgkin lymphoma were analyzed. The Deauville criteria were used for the evaluation of interim PET/CT scans. One hundred and thirteen Hodgkin lymphoma patients underwent staging, interim and restaging PET/CT scans. None of the therapy was modified based on the interim PET/CT results. The median follow-up time was 43.5 months. A total of 62 early stage patients and 51 advanced stage patients were identified. The five-year overall survival rates were 93.4% in the interim PET negative group and 58% in the interim PET positive group (p<0.001). The five-year relapse-free survival rates for the negative and positive groups were 92.7% and 40.8%, respectively (p<0.001). The negative predictive value was 100% in the early stage group and 82.35% in the advanced stage group. By comparison, the positive predictive values were 53.8% and 58.8%, respectively, in these two groups. In the interim PET positive group, patients over 40 years of age had a significantly higher probability of relapse (p=0.057). The routine clinical use of interim PET/CT is highly recommended based on our investigation. However, patients with positive interim PET/CT results required frequent additional evaluations.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban predictive value Hodgkin lymphoma PET/CT
Megjelenés:	Neoplasma. - 62 : 4 (2015), p. 627-34. -
További szerzők:	Barna Sándor (1982-) (kutató orvos) Garai Ildikó (1966-) (radiológus) Simon Zsófia (1977-) (belgyógyász, haematológus) Jóna Ádám (1985-) (orvos) Magyari Ferenc (1985-) (belgyógyász, hematológus) Gergely Lajos (1965-) (belgyógyász, haematológus) Nagy Z. Keresztes Katalin Pettendi Piroska Illés Árpád (1959-) (belgyógyász, haematológus, onkológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM113529
035-os BibID:	(Scopus)85161580863 (WOS)001002920800001
Első szerző:	Nagy Ákos
Cím:	Parallel testing of liquid biopsy (ctDNA) and tissue biopsy samples reveals a higher frequency of mutations in follicular lymphoma / Nagy Ákos, Bátai Bence, Kiss Laura, Gróf Stefánia, Király Péter Attila, Jóna Ádám, Demeter Judit, Sánta Hermina, Bátai Árpád, Pettendi Piroska, Szendrei Tamás, Plander Márk, Körösmezey Gábor, Alizadeh Hussain, Kajtár Béla, Méhes Gábor, Krenács László, Timár Botond, Csomor Judit, Tóth Erika, Schneider Tamás, Mikala Gábor, Matolcsy András, Alpár Donát, Masszi András, Bödör Csaba
Dátum:	2023
ISSN:	0954-6820
Megjegyzések:	Background: Recent genomic studies revealed enhancer of zeste homolog 2 (EZH2) gain-of-function mutations, representing novel therapeutic targets in follicular lymphoma (FL) in around one quarter of patients. However, these analyses relied on single-site tissue biopsies and did not investigate the spatial heterogeneity and temporal dynamics of these alterations. Objectives: We aimed to perform a systematic analysis of EZH2 mutations using paired tissue (tumor biopsies [TB]) and liquid biopsies (LB) collected prior to treatment within the framework of a nationwide multicentric study. Methods: Pretreatment LB and TB samples were collected from 123 patients. Among these, 114 had paired TB and LB, with 39 patients characterized with paired diagnostic and relapse samples available. The EZH2 mutation status and allele burden were assessed using an in-house-designed, highly sensitive multiplex droplet digital PCR assay. Results: EZH2 mutation frequency was found to be 41.5% in the entire cohort. In patients with paired TB and LB samples, EZH2 mutations were identified in 37.8% of the patients with mutations exclusively found in 5.3% and 7.9% of TB and LB samples, respectively. EZH2 mutation status switch was documented in 35.9% of the patients with paired diagnostic and relapse samples. We also found that EZH2 wild-type clones may infiltrate the bone marrow more frequently compared to the EZH2 mutant ones. Conclusion: The in-depth spatio-temporal analysis identified EZH2 mutations in a considerably higher proportion of patients than previously reported. This expands the subset of FL patients who most likely would benefit from EZH2 inhibitor therapy.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk ctDNA ddPCR EZH2 follicular lymphoma liquid biopsy tazemetostat
Megjelenés:	Journal Of Internal Medicine. - 294 : 3 (2023), p. 295-313. -
További szerzők:	Bátai Bence Kiss Laura Gróf Stefánia Király Péter Attila Jóna Ádám (1985-) (orvos) Demeter Judit Sánta Hermina Bátai Árpád Pettendi Piroska Szendrei Tamás Plander Márk Körösmezey Gábor Alizadeh, Hussain Kajtár Béla (1977-) (patológus) Méhes Gábor (1966-) (patológus) Krenács László Timár Botond Csomor Judit Tóth Erika Schneider Tamás (onkológus) Mikala Gábor Matolcsy András Alpár Donát Masszi András Bödör Csaba
Pályázati támogatás:	NKFIH KDP-1022882 Egyéb EFOP-3.6.3-VEKOP-16-2017-00009 EFOP ÚNKP-21-3-II-SE24 Egyéb ÚNKP-22-5-SE-7 Egyéb K21-137948 Egyéb FK20_134253 Egyéb TKP2021-EGA-24 Egyéb TKP2021-NVA-15 Egyéb
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: